China will grant four global drug companies priority-review status to launch groundbreaking new hepatitis C treatments in China, a rare move to open the lucrative market to foreign competitors.
WSJ.com: What's News Asia, Wall Street Journal: What's News Asia
Fri, 04/22/2016 - 3:14am
China will grant four global drug companies priority-review status to launch groundbreaking new hepatitis C treatments in China, a rare move to open the lucrative market to foreign competitors.